Morgan Stanley analyst Patrick Wood raised the firm’s price target on Becton Dickinson (BDX) to $210 from $197 and keeps an Overweight rating on the shares. Going into 2026, MedTech “looks well-positioned on several fronts” as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for “a solid industry setup,” the analyst tells investors in a note for the group on the upcoming year.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson Faces Risks in Biosciences and Diagnostic Merger with Waters
- Becton Dickinson Onclarity HPV Assay, BD Viper receive WHO prequalification
- Starboard takes new stake in Bill Holdings, exits Pfizer position
- Becton Dickinson price target lowered to $202 from $211 at RBC Capital
- Becton Dickinson price target lowered to $210 from $224 at Stifel